Login
Companies $GERN
$0.97 +$0.03 (2.77%) After hours
GERON CORP logo

GERON CORP

geron.com

What Do They Do?

Sells RYTELO, a treatment for certain adults with lower-risk myelodysplastic syndromes, to distributors and specialty pharmacies, and develops imetelstat for other blood cancers.

How Do They Make Money?

Distributors and specialty pharmacies buy RYTELO; sales are counted when the product is delivered, or when consigned product is removed for shipment to a patient.

revenue
SegmentShareRevenue
Revenues Before Adjustments
Sold outright

68%
Chargebacks
−7.8%
Distributor service fees
−2.3%
Government Rebates
−0.8%
Sales Returns And Allowance
−1.2%
Total Gross To Net Adjustments
−12%
Product revenues, net
Sold outright

56%
FY2022: 0.0%

Who Are Their Customers?

In the U.S., third-party distributors and specialty pharmacies buy RYTELO and resell it through specialty pharmacy providers to patients and health care providers; insurers and government programs provide coverage and reimbursement. Geron plans to use third parties for commercialization in the EU.

Do Revenues Turn Into Profits?

No. It lost $83.5M in FY2025.

Operating income, FY2025
−37% of revenue
▲ +61% (Loss) vs FY2024 (−$173.7M, −226%)
Net income, FY2025
−45% of revenue
▲ +52% (Loss) vs FY2024 (−$174.6M, −227%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +27%
vs $47.2M in Q3 FY2025
Net income
▲ Turned profitable
vs −$18.4M in Q3 FY2025
Gross product revenue share of revenue vs 127.4% in Q3 FY2025
  • Aug 6, 2026 Reiterated 2026 RYTELO revenue and operating-expense guidance Geron expects RYTELO net product revenue of $220 million to $240 million and operating expenses of $230 million to $240 million.

Growing. Revenue grew 132.0x in 4 years, from $1.4M in FY2021 to $183.9M in FY2025, about 239% a year.

From drug development to sales The older report described imetelstat as investigational and planned possible U.S. commercialization if approved; the latest report says RYTELO has launched in the U.S. and received authorization in the EU.

EU commercialization approach The older report said Geron might seek partners outside the U.S.; the latest report says it plans to use third parties for EU commercialization rather than commercialize there independently.

Revenue over time
Revenues Before Adjustments Chargebacks Distributor service fees Government Rebates Sales Returns And Allowance Total Gross To Net Adjustments Product revenues, net License Fees And Royalties Royalties
$500M$250M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support